Antihypertensive Treatments, Cognitive Decline, and Dementia
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Chronic hypertension is associated with an increased risk of both vascular dementia and Alzheimer's disease (AD). In this context, the role of anti-hypertensive therapy for the prevention and delay of cognitive decline and dementia is of central importance. Most longitudinal studies have shown a significant inverse association between anti-hypertensive therapies and dementia incidence and for some of these, particularly in AD. Seven randomized, double blind placebo-controlled trials have evaluated the benefit of antihypertensive treatments on cognition. Three of them found positive results in term of prevention of dementia (SYST-EUR) or cognitive decline (PROGRESS, HOPE). Others disclosed non-significant results (MRC, SHEP, SCOPE, HYVET-COG). This discrepancy emphasizes the difficulty to perform such trials: the follow-up has to be long enough to disclose a benefit, a large number of patients is needed for these studies, and because of ethical reasons some anti-hypertensive treatments are often prescribed in the placebo group. Results of the two more recent meta-analyses are inconsistent, possibly due to methodological issues. Antihypertensive treatments could be beneficial to cognitive function by lowering blood pressure and/or by specific neuroprotective effect. Three main antihypertensive subclasses have been associated with a beneficial effect on cognitive function beyond blood pressure reduction (calcium channel blockers, angiotensin converting enzyme inhibitor, angiotensin-AT1-receptor-blockers). Further long-term randomized trials, designed especially to assess a link between antihypertensive therapy and cognitive decline or dementia are therefore needed with cognition as the primary outcome. A low blood pressure threshold that could be deleterious for cognitive function should also be determined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
15-year longitudinal study of blood pressure and dementia
Skoog, I., Nilsson, L., Persson, G., Lernfelt, B., Landahl, S., Palmertz, B., Andreasson, L.-A., Odén, A., & Svanborg, A. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90608-x · Cited by 1,726
Lindsay, J. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf074 · Cited by 1,261 · cited 1×
“Nevertheless, the East Boston cohort study [17] and the Canadian Study of Health and Aging reported no significant associations with dementia [18].”
BackgroundThe age-dependent relation of blood pressure to cognitive function and dementia
Qiu, C., Winblad, B., & Fratiglioni, L. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70141-1 · Cited by 1,138
Angiotensin-Converting Enzyme Inhibitors
Brown, N. J., & Vaughan, D. E. (1998) · Circulation · doi:10.1161/01.cir.97.14.1411 · Cited by 958
Forette, F. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.18.2046 · Cited by 898 · cited 1×
“After the double-blind, placebo-controlled period, all patients withdrawing from double-blind were invited to continue or start the study antihypertensive treatment for a median period of two years (SYST-EUR 2) [25].”
Peters, R., Beckett, N., Forette, F., Tuomilehto, J., Clarke, R., Ritchie, C., Waldman, A., Walton, I., Poulter, R., Ma, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70143-1 · Cited by 770
The role of inflammation in Alzheimer’s disease
Tuppo, E. E., & Arias, H. R. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.07.009 · Cited by 734
Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study
Ruitenberg, A., den Heijer, T., Bakker, S. L. M., van Swieten, J. C., Koudstaal, P. J., Hofman, A., & Breteler, M. M. B. (2005) · Annals of Neurology · doi:10.1002/ana.20493 · Cited by 733
Zhang, X., Zhou, K., Wang, R., Cui, J., Lipton, S. A., Liao, F.-F., Xu, H., & Zhang, Y.-W. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608856200 · Cited by 436
McGuinness, B., Todd, S., Passmore, P., & Bullock, R. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004034.pub3 · Cited by 315 · cited 4×
“In the same way, the Cochrane review suggested a positive effect of nimodipine in AD patients to slow cognitive decline compared to placebo in short-term trials, but no data were available for studies with longer followups [49].”
Influential
Cited by
Cognitive Disorders and Dementia in CKD: The Neglected Kidney-Brain Axis
Bugnicourt, J.-M., Godefroy, O., Chillon, J.-M., Choukroun, G., & Massy, Z. A. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012050536 · Cited by 590
Cardiovascular Risk Factors Promote Brain Hypoperfusion Leading to Cognitive Decline and Dementia
de la Torre, J. C. (2012) · Cardiovascular Psychiatry and Neurology · doi:10.1155/2012/367516 · Cited by 440
Defining the relationship between hypertension, cognitive decline, and dementia: a review
Walker, K. A., Power, M. C., & Gottesman, R. F. (2017) · Current Hypertension Reports · doi:10.1007/s11906-017-0724-3 · Cited by 394
Age-associated reductions in cerebral blood flow are independent from regional atrophy
Chen, J. J., Rosas, H. D., & Salat, D. H. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2010.12.032 · Cited by 360
Karnik, S. S., Unal, H., Kemp, J. R., Tirupula, K. C., Eguchi, S., Vanderheyden, P. M. L., & Thomas, W. G. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.010454 · Cited by 302
Metadata
- Authors
- Duron, E., & Hanon, O.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2010-05-26
- Volume
- 20
- Issue
- 3
- Pages
- 903-914
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2099630336
- Cited by
- 81
- References
- 18
- FWCI
- 5.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antihypertensive Treatments, Cognitive Decline, and Dementia. https://app.cochat.ai/papers/10.3233/jad-2010-091552
- The paper
- Duron, E., & Hanon, O. (2010). Antihypertensive Treatments, Cognitive Decline, and Dementia. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-2010-091552
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.